Viatris reported 2025 revenue of $14.30 billion and Q1 2026 revenue of $3.52 billion. The thesis depends on durable generic-drug cash flow, portfolio pruning, debt reduction, regulatory execution and proof that recent losses are not masking a weakening franchise.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.
